What is Hummingbird Bioscience?
Founded in 2015 and headquartered in Texas, Hummingbird Bioscience operates at the intersection of computational biology and therapeutic development. The company specializes in identifying and neutralizing complex disease targets that have historically eluded traditional pharmaceutical approaches. By leveraging a data-driven, precision-focused methodology, Hummingbird aims to improve patient outcomes in areas of high unmet medical need. Its market position is bolstered by a robust intellectual property portfolio and a collaborative ecosystem of global life science investors, positioning the firm as a key innovator in the next generation of biological drug discovery.
How much funding has Hummingbird Bioscience raised?
Hummingbird Bioscience has raised a total of $275M across 3 funding rounds:
Series B
$25M
Series C
$125M
Series C
$125M
Series B (2020): $25M with participation from SK Holdings Co., Ltd., SEED Capital, Mirae Asset Global Investments, Delian Capital, heritascapital.com, and GNTech Venture Capital
Series C (2021): $125M led by Frazier Healthcare Partners, EDBI, Octagon Capital, Amgen Ventures, and Novo Holdings
Series C (2025): $125M supported by Frazier Healthcare Partners, Altrium, Octagon Capital Group, Novo Holdings, Polaris Partners, Edbi, Morningside Venture Capital, Ally Bridge Group, Droia, Singapore Economic Development Board, Pureos Bioventures, Affinity Asset Advisors, and Amgen
Key Investors in Hummingbird Bioscience
Frazier Healthcare Partners
A private equity and venture capital firm based in Seattle, Washington, specialized in shareholder liquidity, incubation, and growth equity financing for the healthcare sector.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term investments in life science companies.
Ally Bridge Group
A global healthcare investment management firm that specializes in high-impact life science innovation, managing significant capital across private and public equity strategies.
What's next for Hummingbird Bioscience?
The infusion of capital from the most recent financing round is expected to catalyze the advancement of Hummingbird Bioscience's lead candidates through critical clinical phases. Strategic priorities include the expansion of its internal R&D capabilities and the potential for new collaborative partnerships to validate its platform across diverse therapeutic indications. As the company matures, the focus will likely shift toward scaling its operational infrastructure and preparing for potential commercialization pathways, ensuring that its innovative therapeutic modalities can effectively reach patients in global markets.
See full Hummingbird Bioscience company page
